Clinical Trial

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance. RT, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2; Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-06; most recent amendment 2026-04-16.
Trial Details
NCT Number NCT07015853
Lead Sponsor Stephen Shiao
Collaborators: Merck Sharp & Dohme LLC, Incyte Corporation
Conditions TNBC - Triple-Negative Breast Cancer, Breast Cancer
Enrollment 34 participants
Start Date 2026-06
Primary Completion 2033-07 (estimated)
Study Completion 2033-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-20